Leadership Refresh The appointment of Malene Bertelsen as Director for Drug Discovery signals renewed leadership focus; ideal opening to propose strategic, cross functional discovery programs that leverage RG Discovery's integrated offerings from hit finding to clinical candidates.

Specialized Capabilities RG Discovery concentrates on small molecules, macrocycles and peptides, supported by MedChem, computational science, ADME/physchem, in vitro biology and bioanalysis, offering a compelling partner for early discovery programs and complex synthetic needs.

End to End CRO Analytical Services and Advanced Chemistry enable end to end CRO execution, including qualitative and quantitative analysis, NMR structure studies, chiral separations, and synthesis of diverse compounds, which can reduce vendor management and timelines for biotech customers.

Collaborative Model A track record of research collaborations with biotech and academic partners, plus AI based collaboration history with Desupervised, positions RG Discovery as a flexible partner for co development and efficiency focused R&D programs.

Regional Access Based in Lund in the Medicon Valley, RG Discovery sits in a dense biotech and pharma hub with potential for regional collaborations and co location engagements with nearby startups and larger CROs seeking specialized capabilities in small molecules and analytical chemistry.